Ligand Pharmaceuticals (LGND) Other Non Operating Income (2010 - 2026)

Ligand Pharmaceuticals has reported Other Non Operating Income for 17 years, with the latest figure at -$1.2 million in Q1 2026.

• Quarterly Other Non Operating Income fell 365.24% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$335000.0 (up 96.2% YoY) and the FY2025 annual result came in at -$89000.0, up 99.41% from the prior year.
• Other Non Operating Income fell to -$1.2 million in Q1 2026 per LGND's latest filing, from -$89000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $2.3 million in Q1 2022 and troughed at -$7.8 million in Q3 2024.
• A 5-year average of -$939923.1 and a median of -$443000.0 in 2025 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income soared 321.65% in 2022, then slumped 365.24% in 2026.
• Over 5 years, Other Non Operating Income stood at -$5.0 million in 2022, then surged by 82.47% to -$873000.0 in 2023, then sank by 66.09% to -$1.4 million in 2024, then jumped by 93.86% to -$89000.0 in 2025, then slumped by 1220.22% to -$1.2 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$1.2 million, -$89000.0, and -$443000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.